Financing ·
InflaRx raises €119.3M from $2.00/share equity offering and reports Q3 loss
IFRXInflaRx N.V.
InflaRx N.V. completed an underwritten public offering of 75,000,000 ordinary shares at a price of $2.00 per share in May 2026, generating net proceeds of €119.3 million ($140.4 million). The company reported a net loss of €18.7 million for the nine months ended September 30, 2026, compared to a loss of €35.0 million in the prior year period. Operating expenses decreased significantly due to the discontinuation of active sales activities for GOHIBIC (vilobelimab) in the United States and lower research and development costs. As of September 30, 2026, the company held €81.3 million in cash and cash equivalents plus €71.9 million in marketable securities, providing sufficient liquidity to fund operations through the end of 2029. InflaRx N.V. is a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system.